| Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates |
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference |
- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - |
globenewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know |
Vigil Neuroscience (VIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-17 15:00:19 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates |
– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum |
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025, at 9:00 a.m. |
globenewswire.com |
2025-03-11 09:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) |
NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2025-02-20 13:17:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference |
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET. |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 |
On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer's disease. |
benzinga.com |
2025-01-23 13:33:18 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease |
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer's disease (AD) - |
globenewswire.com |
2025-01-23 09:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones |
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 – |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience initiated with an Outperform at William Blair |
William Blair analyst Sarah Schram initiated coverage of Vigil Neuroscience with an Outperform rating. |
https://thefly.com |
2024-12-03 18:59:54 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) |
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-10-09 15:58:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 |
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company. |
globenewswire.com |
2024-09-17 11:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present at Cantor Global Healthcare Conference |
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET. |
globenewswire.com |
2024-09-16 20:05:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present at Upcoming September Investor Conferences |
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences. |
globenewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) |
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-08-23 15:47:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update |
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an update on recent progress. |
globenewswire.com |
2024-08-13 11:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease |
- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer's disease (AD) - |
globenewswire.com |
2024-07-24 11:00:00 |
Czytaj oryginał (ang.) |
| Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference |
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually. |
globenewswire.com |
2024-07-18 20:05:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP |
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today an update following a Type C Meeting with the U.S. Food and Drug Administration (FDA) to its clinical development strategy for its IGNITE clinical trial evaluating iluzanebart in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). |
globenewswire.com |
2024-07-18 11:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) |
NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2024-07-08 12:30:00 |
Czytaj oryginał (ang.) |
| Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E |
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX). |
zacks.com |
2024-06-27 13:06:32 |
Czytaj oryginał (ang.) |
| Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? |
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each. |
investorplace.com |
2024-06-27 12:11:40 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi |
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. |
globenewswire.com |
2024-06-27 06:00:00 |
Czytaj oryginał (ang.) |
| Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases |
LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri. |
businesswire.com |
2024-06-26 05:00:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition |
Penny stocks have a unique appeal– one that only strong-stomached, risky-taking investors find appetizing. This is for good reason– these stocks are insanely volatile. |
investorplace.com |
2024-06-11 10:30:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition |
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. |
investorplace.com |
2024-06-11 10:00:00 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present in Upcoming June Investor Conferences |
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management's participation at two upcoming investor conferences. |
globenewswire.com |
2024-05-30 11:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy |
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-05-28 17:01:06 |
Czytaj oryginał (ang.) |
| Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference |
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T. |
globenewswire.com |
2024-05-08 11:40:00 |
Czytaj oryginał (ang.) |